Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory Bowel Disease I: Introduction01:26

Inflammatory Bowel Disease I: Introduction

Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Novel Viscoelastic Tool Highlighting Severity-Dependent Platelet Dysfunction in Cirrhosis.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Rosy Discolouration in an Alpine Chapel: Beyond Salt Dependence.

Microbial ecology·2026
Same author

Managing Coagulation Abnormalities, Bleeding, and Thrombosis in Patients with Cirrhosis.

Journal of general internal medicine·2026
Same author

Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2- breast cancer patients with bone metastases.

The oncologist·2026
Same author

Multidisciplinary Clinic Approach Improves Immunotherapy Treatment Outcomes in Unresectable Hepatocellular Carcinoma: A Multicentre Retrospective Study.

Liver cancer·2026
Same author

Locally advanced rectal cancer: what patients and practitioners should know about non-operative management.

EClinicalMedicine·2026

Related Experiment Video

Updated: Jun 18, 2026

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Increased thrombin generation in inflammatory bowel diseases.

Simone Saibeni1, Valeria Saladino, Veena Chantarangkul

  • 1Department of Internal Medicine and Hepatology, Azienda Ospedaliera Fatebenefratelli e Oftalmico, Milan, Italy.

Thrombosis Research
|November 17, 2009
PubMed
Summary

Endogenous thrombin potential (ETP) is elevated in inflammatory bowel disease (IBD) patients, particularly those with active disease or high C-reactive protein (CRP). This suggests ETP may help assess thrombosis risk in IBD.

More Related Videos

Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease
05:08

A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease

Published on: March 1, 2022

Related Experiment Videos

Last Updated: Jun 18, 2026

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease
05:08

A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease

Published on: March 1, 2022

Area of Science:

  • Coagulation science
  • Gastroenterology
  • Thrombosis research

Background:

  • Inflammatory bowel diseases (IBD) are linked to increased thrombotic risk.
  • The etiology of this heightened risk remains unclear.
  • Endogenous thrombin potential (ETP) is a novel parameter for evaluating coagulation disorders.

Purpose of the Study:

  • To investigate ETP levels in IBD patients.
  • To correlate ETP with clinical and biochemical markers.
  • To assess ETP as a potential indicator of hypercoagulability in IBD.

Main Methods:

  • Seventy-four IBD patients and 74 healthy controls were studied.
  • ETP was measured using tissue factor and phospholipid activation, with and without thrombomodulin.
  • Results were analyzed in relation to C-reactive protein (CRP) levels and disease activity.

Main Results:

  • ETP was significantly higher in IBD patients compared to controls when measured with thrombomodulin (p<0.001).
  • The ETP ratio (with/without thrombomodulin), indicating hypercoagulability, was also significantly elevated in IBD patients (p<0.006).
  • Elevated ETP correlated with higher CRP levels and clinically active disease (p<0.001).

Conclusions:

  • ETP, particularly when measured with thrombomodulin or as a ratio, is increased in IBD patients.
  • Elevated ETP is more pronounced in IBD patients with high CRP or active disease.
  • ETP shows potential as a biomarker for assessing thrombosis risk in IBD.